Mark S Sulkowski Selected Research

Protease Inhibitors (Protease Inhibitor)

1/2017	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
2/2016	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
7/2014	All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
5/2014	Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
1/2014	Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
1/2014	Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
5/2013	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
2/2013	HCV therapy in HIV-infected patients.
9/2012	Factors that predict response of patients with hepatitis C virus infection to boceprevir.
4/2012	Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark S Sulkowski Research Topics

Disease

74	Infections 11/2022 - 01/2002
35	Fibrosis (Cirrhosis) 11/2022 - 01/2004
34	Chronic Hepatitis C 12/2021 - 11/2003
34	Hepatitis C 01/2021 - 01/2002
28	Coinfection 10/2022 - 05/2003
23	Liver Diseases (Liver Disease) 12/2021 - 01/2004
13	Anemia 06/2016 - 01/2003
11	Hepatitis 12/2021 - 01/2002
10	HIV Infections (HIV Infection) 12/2021 - 01/2004
6	Hepatitis B 10/2022 - 11/2004
5	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019 - 01/2005
4	Acquired Immunodeficiency Syndrome (AIDS) 01/2020 - 07/2002
4	Insulin Resistance 01/2016 - 01/2011
4	Fatigue 11/2015 - 04/2005
4	Persistent Infection 01/2015 - 03/2011
4	Nausea 05/2013 - 05/2004
3	Viremia 01/2022 - 10/2007
3	Disease Progression 05/2021 - 07/2012
3	Substance-Related Disorders (Drug Abuse) 01/2020 - 09/2016
3	Hepatocellular Carcinoma (Hepatoma) 11/2014 - 01/2004
3	Body Weight (Weight, Body) 01/2014 - 08/2009
3	Headache (Headaches) 05/2013 - 05/2004
3	Drug-Related Side Effects and Adverse Reactions 08/2012 - 02/2012
2	Chronic Hepatitis B 11/2022 - 10/2007
2	Alcoholism (Alcohol Abuse) 01/2016 - 03/2011
2	Communicable Diseases (Infectious Diseases) 07/2014 - 09/2004
2	Hemolytic Anemia 01/2014 - 02/2012
2	End Stage Liver Disease 07/2012 - 01/2004
2	Neutropenia 07/2011 - 01/2008
2	Hyperglycemia 03/2005 - 08/2003
1	Fatty Liver 10/2022

Drug/Important Bio-Agent (IBA)

62	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 11/2002
30	Antiviral Agents (Antivirals)IBA 12/2021 - 01/2004
23	InterferonsIBA 01/2018 - 08/2005
21	RNA (Ribonucleic Acid)IBA 12/2021 - 01/2004
18	SofosbuvirIBA 01/2021 - 05/2013
16	Interferon-alpha (Interferon Alfa)IBA 11/2015 - 05/2002
14	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 01/2002
10	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 05/2014 - 03/2011
8	Ritonavir (Norvir)FDA Link 01/2020 - 11/2004
8	Pharmaceutical PreparationsIBA 01/2017 - 04/2005
7	ombitasvirIBA 01/2020 - 01/2014
7	dasabuvirIBA 01/2020 - 01/2014
7	paritaprevirIBA 01/2020 - 01/2014
7	telaprevirIBA 04/2014 - 09/2011
6	sofosbuvir drug combination ledipasvirIBA 01/2022 - 09/2015
6	peginterferon alfa-2a (Pegasys)FDA Link 04/2014 - 08/2006
5	Epoetin Alfa (Epogen)FDA Link 08/2005 - 01/2003
4	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 05/2021
4	daclatasvirIBA 01/2017 - 01/2014
3	glecaprevir and pibrentasvirIBA 12/2019 - 01/2017
3	BilirubinIBA 10/2017 - 01/2014
3	AlbuminsIBA 10/2017 - 01/2006
3	ledipasvirIBA 12/2016 - 07/2014
3	Erythropoietin FDA Link 06/2016 - 03/2013
3	faldaprevirIBA 05/2016 - 06/2013
3	SimeprevirIBA 02/2016 - 07/2014
3	NucleotidesIBA 09/2015 - 05/2013
3	peginterferon alfa-2b (Pegintron)FDA Link 05/2014 - 08/2009
2	Reverse Transcriptase InhibitorsIBA 11/2022 - 08/2003
2	entecavir FDA Link 11/2022 - 05/2008
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 05/2021
2	Human immunodeficiency virus 1 p16 proteaseIBA 01/2020 - 03/2004
2	Cocaine (Cocaine HCl)IBA 01/2019 - 01/2018
2	Heroin (Diamorphine)IBA 01/2019 - 01/2018
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 09/2016 - 08/2011
2	dimemorfan (AT 17)IBA 03/2015 - 06/2007
2	Raltegravir Potassium FDA Link 03/2015 - 01/2014
2	Atazanavir Sulfate (Reyataz)FDA Link 03/2015 - 01/2014
2	Proteins (Proteins, Gene)FDA Link 07/2014 - 01/2006
2	Alanine Transaminase (SGPT)IBA 03/2014 - 08/2011
2	Hemoglobins (Hemoglobin)IBA 03/2013 - 01/2003
2	CreatinineIBA 03/2013 - 07/2011
2	HCV NS3-4A Protease InhibitorsIBA 02/2013 - 02/2012
2	Glucose (Dextrose)FDA LinkGeneric 07/2011 - 08/2003
2	albinterferon alfa-2bIBA 10/2010 - 02/2009
2	Interferon alpha-2 (Roferon-A)FDA Link 02/2009 - 04/2004
2	Lamivudine (Epivir)FDA Link 05/2008 - 01/2004
2	EnzymesIBA 01/2005 - 11/2004
1	Hepatitis B e AntigensIBA 11/2022
1	LipidsIBA 10/2022
1	Lipoproteins (Lipoprotein)IBA 10/2022
1	TabletsIBA 01/2022
1	Circular DNAIBA 01/2022
1	Surface Antigens (Surface Antigen)IBA 01/2022
1	tenofovir alafenamideIBA 05/2021
1	Immunoglobulins (Immunoglobulin)IBA 05/2021
1	Lipopolysaccharide ReceptorsIBA 01/2020
1	Cytochrome P-450 CYP2B1 (PROD)IBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020

Therapy/Procedure

64	Therapeutics 01/2021 - 01/2002
11	Art Therapy 09/2016 - 11/2004
8	Liver Transplantation 05/2021 - 09/2004
8	Drug Tapering 04/2014 - 01/2003
6	Continuity of Patient Care 12/2020 - 01/2015
6	Highly Active Antiretroviral Therapy (HAART) 01/2015 - 07/2002
4	Aftercare (After-Treatment) 12/2019 - 12/2002
4	Retreatment 10/2017 - 04/2014
2	Duration of Therapy 01/2020 - 02/2016
2	Injections 01/2018 - 04/2005